
Persistence pays off for Kala
The company’s Eysuvis looks set to be approved for dry eye disease, but meeting expectations in this tough market will not be easy.
The company’s Eysuvis looks set to be approved for dry eye disease, but meeting expectations in this tough market will not be easy.